Weekly CAF chemotherapy for advanced breast cancer patients

Wei Shou Hwang, Chao A. Hsiung, Wann Sheng Ko, Chang Chung Wang, Jang Yang Chang, Gi Ming Lai, Ruey Kuen Hsieh, Chao Jung Tsao, Li Tzong Chen, Chi Kong Law, Ann Lii Cheng, Sheng F. Fan, Cheng Hwai Tzeng, Tzeon Jye Chiou, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalOncology
Volume54
Issue number4
Publication statusPublished - Jul 1997
Externally publishedYes

Fingerprint

Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Intravenous Injections
Vomiting
Appointments and Schedules
Heart Failure
Confidence Intervals
Survival
Therapeutics

Keywords

  • Breast cancer, advanced
  • CAF, weekly
  • Phase II trial

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hwang, W. S., Hsiung, C. A., Ko, W. S., Wang, C. C., Chang, J. Y., Lai, G. M., ... Whang-Peng, J. (1997). Weekly CAF chemotherapy for advanced breast cancer patients. Oncology, 54(4), 293-297.

Weekly CAF chemotherapy for advanced breast cancer patients. / Hwang, Wei Shou; Hsiung, Chao A.; Ko, Wann Sheng; Wang, Chang Chung; Chang, Jang Yang; Lai, Gi Ming; Hsieh, Ruey Kuen; Tsao, Chao Jung; Chen, Li Tzong; Law, Chi Kong; Cheng, Ann Lii; Fan, Sheng F.; Tzeng, Cheng Hwai; Chiou, Tzeon Jye; Whang-Peng, Jacqueline.

In: Oncology, Vol. 54, No. 4, 07.1997, p. 293-297.

Research output: Contribution to journalArticle

Hwang, WS, Hsiung, CA, Ko, WS, Wang, CC, Chang, JY, Lai, GM, Hsieh, RK, Tsao, CJ, Chen, LT, Law, CK, Cheng, AL, Fan, SF, Tzeng, CH, Chiou, TJ & Whang-Peng, J 1997, 'Weekly CAF chemotherapy for advanced breast cancer patients', Oncology, vol. 54, no. 4, pp. 293-297.
Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM et al. Weekly CAF chemotherapy for advanced breast cancer patients. Oncology. 1997 Jul;54(4):293-297.
Hwang, Wei Shou ; Hsiung, Chao A. ; Ko, Wann Sheng ; Wang, Chang Chung ; Chang, Jang Yang ; Lai, Gi Ming ; Hsieh, Ruey Kuen ; Tsao, Chao Jung ; Chen, Li Tzong ; Law, Chi Kong ; Cheng, Ann Lii ; Fan, Sheng F. ; Tzeng, Cheng Hwai ; Chiou, Tzeon Jye ; Whang-Peng, Jacqueline. / Weekly CAF chemotherapy for advanced breast cancer patients. In: Oncology. 1997 ; Vol. 54, No. 4. pp. 293-297.
@article{a7991f56bb9a41b695a3c513fff46b03,
title = "Weekly CAF chemotherapy for advanced breast cancer patients",
abstract = "In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52{\%} (95{\%} confidence interval, 41-63{\%}). Of the evaluable patients, 15{\%} had complete response and 37{\%} had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.",
keywords = "Breast cancer, advanced, CAF, weekly, Phase II trial",
author = "Hwang, {Wei Shou} and Hsiung, {Chao A.} and Ko, {Wann Sheng} and Wang, {Chang Chung} and Chang, {Jang Yang} and Lai, {Gi Ming} and Hsieh, {Ruey Kuen} and Tsao, {Chao Jung} and Chen, {Li Tzong} and Law, {Chi Kong} and Cheng, {Ann Lii} and Fan, {Sheng F.} and Tzeng, {Cheng Hwai} and Chiou, {Tzeon Jye} and Jacqueline Whang-Peng",
year = "1997",
month = "7",
language = "English",
volume = "54",
pages = "293--297",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Weekly CAF chemotherapy for advanced breast cancer patients

AU - Hwang, Wei Shou

AU - Hsiung, Chao A.

AU - Ko, Wann Sheng

AU - Wang, Chang Chung

AU - Chang, Jang Yang

AU - Lai, Gi Ming

AU - Hsieh, Ruey Kuen

AU - Tsao, Chao Jung

AU - Chen, Li Tzong

AU - Law, Chi Kong

AU - Cheng, Ann Lii

AU - Fan, Sheng F.

AU - Tzeng, Cheng Hwai

AU - Chiou, Tzeon Jye

AU - Whang-Peng, Jacqueline

PY - 1997/7

Y1 - 1997/7

N2 - In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.

AB - In a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response rate was 52% (95% confidence interval, 41-63%). Of the evaluable patients, 15% had complete response and 37% had partial response. The median survival after therapy was 15.6 months, the median time to progression was 6.8 months and the median duration of response was 9.1 months. The main toxicities were mild vomiting and moderate myelosuppression. There was only 1 patient who experienced heart failure. Weekly CAF appears to have an efficacy with tolerable side effects comparable to standard CAF with an every-3-week schedule.

KW - Breast cancer, advanced

KW - CAF, weekly

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0030904233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030904233&partnerID=8YFLogxK

M3 - Article

C2 - 9216853

AN - SCOPUS:0030904233

VL - 54

SP - 293

EP - 297

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -